Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sales & Earnings In Brief

This article was originally published in The Tan Sheet

Executive Summary

Bristol-Myers Squibb: Enfamil infant formula drives U.S. nutritionals sales up 5% to $267 mil. in the second quarter, Bristol reports July 28. The product also spurred international nutritionals results up 10% to $281 mil. to lead worldwide nutritionals business to $548 mil. in total revenues, up 7% over the prior-year period. The unit was a strong performer for Bristol's overall business, which recorded relatively flat sales of $4.9 bil. and an 89% increase in net earnings to $991 mil. The company's consumer medicines sales declined 16% to $57 mil.; Bristol recently announced plans to divest the unit to Novartis, a transaction expected to close by the end of the third quarter (1"The Tan Sheet" July 18, 2005, p. 3)...

You may also be interested in...



Novartis Purchase Of Bristol OTCs Has Excedrin Written All Over It

Novartis will enter the U.S. over-the-counter analgesics market with Excedrin as part of the purchase of Bristol-Myers Squibb's OTC portfolio

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

People In Brief

Perrigo promotes in pricing, planning

Topics

UsernamePublicRestriction

Register

LL029263

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel